RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
GlaxoSmithKline said its specialist HIV company had received marketing authorisation from the European Commission for its drug to treat advanced stage HIV infections in adults and adolescents above the age of 12 and weighing at least 40 kg. ViiV Healthcare, which is majority owned by GSK and with Pfizer Inc and Shionogi Ltd as shareholders, got the U.S. Food and Drug Administration approval for the treatment Dovato in April. Source: Reuters
